Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Abcam Signs License Agreement with Pfizer

Published: Wednesday, June 12, 2013
Last Updated: Wednesday, June 12, 2013
Bookmark and Share
Company to supply a range of authentic Pfizer compounds to researchers.

Abcam Plc. has announced that it has entered into a license agreement with Pfizer. Under the terms of the agreement, Abcam’s Biochemicals division will supply a range of authentic Pfizer compounds for use as pre-clinical research tools by researchers worldwide, alongside the Abcam Biochemicals range of over 2000 bioactive small molecules.

The agreement covers a broad group of Pfizer compounds including atorvastatin, doxorubicin, nifedipine and bosutinib, all of which are widely used in pre-clinical research.

The Pfizer research compounds and Abcam Biochemicals range will support pre-clinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.

Steve Roome, General Manager of Abcam Biochemicals, commented: “We are delighted to have signed the license agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology
Abcam Partners with A*STAR’s Institute of Molecular and Cell Biology.
Thursday, January 08, 2015
Abcam plc Announces Board Appointment
Appointment of Sue Harris as a non-Executive Director on the Company’s Board.
Saturday, December 13, 2014
Abcam Appoints Yvonne Chien as Chief Digital Officer
Abcam’s leadership team strengthened by new appointments.
Saturday, December 13, 2014
Abcam Wins ‘Best Use of Digital Media’ at Life Science Industry Awards
Awards recognise the world’s top performing life science suppliers.
Wednesday, November 19, 2014
Abcam and Cell Marque Sign Global Strategic Marketing Agreement
Partnership extends Abcam’s reach within in vitro diagnostics market.
Saturday, September 06, 2014
Abcam Establishes New Direct Service for Australia and New Zealand
New service will offer researchers improved delivery times and direct technical support.
Tuesday, August 12, 2014
Abcam Announces Winner of 15 Discoveries Contest
Contest celebrates scientific breakthroughs with $15,000 research grant.
Tuesday, February 04, 2014
Abcam to Open Office in Shanghai
New office will provide dedicated support to Chinese customers.
Tuesday, January 21, 2014
Abcam Named AIM Company of the Year
The AIM awards celebrate outstanding achievement of quoted companies and entrepreneurs who have harnessed AIM to help them fulfil their ambition and growth potential in the last twelve months.
Monday, October 14, 2013
Abcam Appoints Alan Hirzel as Chief Marketing Officer
New role will support future growth strategies at Abcam.
Friday, June 28, 2013
Scientific News
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Snapshot Turns T Cell Immunology on its Head
New research may have implications for 1 diabetes sufferers.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
New Approach to Treating Heparin-induced Blood Disorder
A potential treatment for a serious clotting condition that can strike patients who receive heparin to treat or prevent blood clots may lie within reach by elucidating the structure of the protein complex at its root.
3 Ways Viruses Have Changed Science for the Better
Viruses are really good at what they do, and we’ve been able to harness their skills to learn about – and potentially improve – human health in several ways.
Mixed Up Cell Transportation Key Piece of ALS and Dementia Puzzle
Researchers from the University of Toronto are one step closer to solving this incredibly complex puzzle, offering hope for treatment.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Four Gut Bacteria Decrease Asthma Risk in Infants
New research by scientists at UBC and BC Children’s Hospital finds that infants can be protected from getting asthma if they acquire four types of gut bacteria by three months of age.
Escape Prevention
Studying flu virus structure brings us a step closer to a permanent vaccine.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos